Hepatic‐Targeted Liposomes‐Ginger‐Derived Exosomes Hybrid Nanocarrier for Synergistic Alleviation of Obesity‐Induced Nonalcoholic Steatohepatitis
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.202503076 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Yuhong Ma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, P. R. China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Liposomes, Exosomes, Obesity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Continued consumption of a high‐calorie diet results in the excessive accumulation of lipids in visceral adipose tissue, thereby increasing the risk of nonalcoholic steatohepatitis (NASH). Herein, ginger‐derived exosomes (G‐Exos) loaded with berberine (G‐Exos@B) to facilitate targeted delivery to the liver through the formation of GR‐Exos@B via the coalescence of ursodeoxycholic acid (UDCA)‐introduced liposomes (RAL) for effective NASH intervention are developed. The introduction of G‐Exos significantly equipped GR‐Exos@B to effectively overcome the multi‐intestinal barrier, facilitating their exit from the cell in an intact form. Interestingly, the hepatic‐targeting of RAL allowed GR‐Exos to penetrate the liver more effectively than G‐Exos, resulting in 2.39‐fold greater accumulation in the liver. In vivo experiments revealed that dual ROS depletion by berberine and GR‐Exos synergistically enhanced the therapeutic effect against inhibited oxidative stress and hepatocellular steatosis compared to GR‐Exos. Additionally, the macrophage‐targeting capability of G‐Exos is leveraged to suppress the activation of hepatic NLRP3 inflammasome complexes, transitioning from an M1 pro‐inflammatory to an M2 anti‐inflammatory state, which helped diminish hepatic macrophage levels and subsequently reduce lipid accumulation. Meanwhile, GR‐Exos@B improved insulin sensitivity primarily by strengthening the AMPK/AKT/IRS‐1 signaling pathway and inhibiting GSK3‐β function. Hence, GR‐Exos@B shows promise as a potential strategy for alleviating obesity‐induced NASH therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Engineering, School of Engineering, China Pharmaceutical University, Nanjing, 211198, P. R. China.
ORCID-Profile: Hongliang Qian
Förderung
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Ma, Y., Ma, Y., Yuan, Z., Han, J., Huang, D., & Qian, H. (2026). Hepatic‐Targeted Liposomes‐Ginger‐Derived Exosomes Hybrid Nanocarrier for Synergistic Alleviation of Obesity‐Induced Nonalcoholic Steatohepatitis. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202503076
Vancouver
Ma Y, Ma Y, Yuan Z, Han J, Huang D, Qian H. Hepatic‐Targeted Liposomes‐Ginger‐Derived Exosomes Hybrid Nanocarrier for Synergistic Alleviation of Obesity‐Induced Nonalcoholic Steatohepatitis. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.202503076
BibTeX
@article{Ma2026,
author = {Ma, Yuhong and Ma, Yukun and Yuan, Zhen and Han, Jingxian and Huang, Dechun and Qian, Hongliang},
title = {Hepatic‐Targeted Liposomes‐Ginger‐Derived Exosomes Hybrid Nanocarrier for Synergistic Alleviation of Obesity‐Induced Nonalcoholic Steatohepatitis},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.202503076}
}
EUVIMED